Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01181453 · ClinicalTrials.gov registry record · Phase 3

Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers

A Phase 3 study, sponsored by Organogenesis.

Completed
Registry status
Phase 3
Development phase
314
Enrollment target

NCT01181453: Completed Phase 3 study, sponsored by Organogenesis.

NCT01181453 is a Phase 3 study that has completed, run by Organogenesis. The registered enrollment target is 314 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01181453, a Phase 3 study, has completed, sponsored by Organogenesis.

COMPLETED
Registry status
Phase 3
Development phase
314 participants
Enrollment target

Study Summary

This study randomly assigns patients with diabetic foot ulcers to receive standard therapy (surgical debridement, saline-moistened gauze and offloading) alone or standard therapy plus Dermagraft(R). Dermagraft is a device containing live human fibroblasts grown on an absorbable Vicryl mesh. Patients are seen weekly until they heal or the 12-week treatment period is complete.

Interventions

  • OTHER Comparator
  • DEVICE Dermagraft

Trial Details

FieldValue
Enrollment Target 314 participants
Start Date 1998-12
Est. Completion 2000-03
Phase Phase 3
Organogenesis

20 total trials

What the finished NCT01181453 record still lists

NCT01181453 is an interventional study that assigns participants to a tested intervention. The registered 314 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower).

The record links to 0 conditions, and to 2 interventions - of which Comparator is the first listed.

NCT01181453 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01181453 about?

NCT01181453 is a clinical study titled "Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers". This study randomly assigns patients with diabetic foot ulcers to receive standard therapy (surgical debridement, saline-moistened gauze and offloading) alone or standard therapy plus Dermagraft(R). Dermagraft is a device containing live human fibroblasts grown on an absorbable Vicryl mesh. Patients...

What is the current status of trial NCT01181453?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 314 participants. The study started on 1998-12. Estimated completion is 2000-03.

What interventions are being tested in trial NCT01181453?

The interventions under investigation include: Comparator (OTHER), Dermagraft (DEVICE).

Who is sponsoring clinical trial NCT01181453?

This trial is sponsored by Organogenesis, which has 20 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01181453's enrollment target sits among peer trials

314 1096th of 2000 higher than 900 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03866382 · 314 participants · Phase 2

    Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • NCT04500756 · 314 participants · Phase 2

    Limiting AAA With Metformin (LIMIT) Trial

  • NCT06167746 · 314 participants · Phase 3

    iCare4Me Transitions

  • NCT06883097 · 314 participants · NA

    Quitting Matters Human Immunodeficiency Virus Hybrid Trial

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01181453, the US trial registry maintained by the National Library of Medicine. NCT01181453 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.